secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001664710-25-000086
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros net loss narrows to $7.3M in Q3; cash runway into H1 2028
---------------------------------------------------------------

- Net loss of $7.3M in Q3 2025 versus $53.0M in Q3 2024, driven by Takeda license revenue.
- R&D expenses fell to $19.5M from $49.2M after elritercept transition to Takeda.
- Cash and equivalents $693.5M; board authorized $375M return to stockholders.
- Takeda plans to initiate Phase 3 trial of elritercept in first-line myelodysplastic syndromes.
- Keros expects to fund operations into H1 2028 after capital return.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000086/0001664710-25-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000086/kros-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer